Market Place
Sourcing Support
Avalo Therapeutics to Present at Upcoming Investor Conferences
11 Nov 2024 //
GLOBENEWSWIRE
Avalo Reports Q3 2024 Financial Results & Recent Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
Avalo Doses First Patient In AVTX-009 Phase 2 LOTUS Trial
08 Oct 2024 //
GLOBENEWSWIRE
Avalo Announces Participation in September Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Avalo Therapeutics Appoints Dr. Mittie Doyle As Chief Medical Officer
16 Jul 2024 //
GLOBENEWSWIRE
Avalo Therapeutics Welcomes Chief Medical Officer
16 Jul 2024 //
CONTRACT PHARMA
Avalo Announces Active IND For AVTX-009 In Hidradenitis Suppurativa
09 Jul 2024 //
GLOBENEWSWIRE
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
24 Jun 2024 //
GLOBENEWSWIRE
Avalo To Present At Oppenheimer Novel Targets In Immunology Summit
17 Jun 2024 //
GLOBENEWSWIRE
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
13 May 2024 //
GLOBENEWSWIRE
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
02 Apr 2024 //
GLOBENEWSWIRE
Avalo Reports 2023 Financial Results and Provides Business Updates
29 Mar 2024 //
GLOBENEWSWIRE
Avalo snaps up AlmataBio for ex-Lilly inflammatory drug
28 Mar 2024 //
FIERCE BIOTECH
Avalo Acquires Anti-IL-1 mAb and Announces Private Placement of up to $185M
27 Mar 2024 //
GLOBENEWSWIRE
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
27 Dec 2023 //
GLOBENEWSWIRE
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
07 Dec 2023 //
GLOBENEWSWIRE
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
09 Nov 2023 //
GLOBENEWSWIRE
Avalo Completes Divestiture of AVTX-800 Series
31 Oct 2023 //
GLOBENEWSWIRE
Avalo Successfully Eliminates $35 Million Debt Paving the Way for Future Growth
26 Sep 2023 //
GLOBENEWSWIRE
Avalo Enters into Agreement to Divest AVTX-800 Series
12 Sep 2023 //
GLOBENEWSWIRE
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Avalo Reports Second Quarter 2023 Financial Results & Provides Business Updates
03 Aug 2023 //
GLOBENEWSWIRE
Avalo spirals amid default, spurring attempt to sell assets
03 Aug 2023 //
FIERCE BIOTECH
Avalo to Participate in SVB Securities Therapeutics Forum
06 Jul 2023 //
GLOBENEWSWIRE
Avalo looks to LIGHT as lead asset fails phase 2, shares fall
27 Jun 2023 //
FIERCE BIOTECH
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002
26 Jun 2023 //
GLOBENEWSWIRE
Avalo looks to LIGHT as lead asset fails phase 2, shares fall
26 Jun 2023 //
FIERCE BIOTECH
Avalo to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Avalo Announces Appointment of Michael Croft to its Scientific Advisory Board
22 May 2023 //
GLOBENEWSWIRE
Avalo to Present at ATS 2023 Respiratory Innovation Summit
15 May 2023 //
GLOBENEWSWIRE
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
10 May 2023 //
GLOBENEWSWIRE
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
04 May 2023 //
GLOBENEWSWIRE
Avalo Reports 2022 Financial Results and Provides Business Updates
29 Mar 2023 //
GLOBENEWSWIRE
Avalo to Present at Oppenheimer`s 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Avalo Announces Proposed Public Offering of Common Stock and Warrants
02 Feb 2023 //
GLOBENEWSWIRE
Avalo Announces Pricing of $15 Million Public Offering of Common Stock
02 Feb 2023 //
GLOBENEWSWIRE
Avalo Announces Enrollment of 80 Patients in PII PEAK Trial of AVTX-002
17 Jan 2023 //
GLOBENEWSWIRE
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
07 Nov 2022 //
GLOBENEWSWIRE
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 Nov 2022 //
GLOBENEWSWIRE
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
06 Sep 2022 //
GLOBENEWSWIRE
Avalo to Present at the H.C. Wainwright Global Investment Conference
01 Sep 2022 //
PRESS RELEASE
Avalo Therapeutics Announces Board Changes
11 Aug 2022 //
GLOBENEWSWIRE
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
10 Aug 2022 //
BENZINGA
Avalo Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Avalo Tx Begins Dosing in the AVTX-803 Pivotal Trial (LADDER) for LAD II
02 Aug 2022 //
GLOBENEWSWIRE
Apollo lands inflammatory antibody from Avalo for $90M biobucks
01 Aug 2022 //
FIERCEBIOTECH
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
06 Jul 2022 //
GLOBENEWSWIRE
Avalo to Present at the 2022 Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Avalo Announces First Patient Dosed in PII PEAK Trial of AVTX-002 in NEA
18 May 2022 //
GLOBENEWSWIRE
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
17 May 2022 //
GLOBENEWSWIRE
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates
05 May 2022 //
GLOBENEWSWIRE
Avalo to Present at Oppenheimer`s 32nd Annual Healthcare Conference
08 Mar 2022 //
GLOBENEWSWIRE
Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
02 Mar 2022 //
GLOBENEWSWIRE
Avalo Therapeutics shuffles leadership team
17 Feb 2022 //
ENDPTS
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
10 Jan 2022 //
PRESS RELEASE
Avalo Reports Positive Phase 1b Results for AVTX-002 in Crohn`s Disease
06 Jan 2022 //
GLOBENEWSWIRE
